The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | ASH 2020: Key findings in post-BTK mantle cell lymphoma
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, discusses key data presented at ASH 2020 on mantle cell lymphoma. Treatment options for MCL patients following failure of BTK inhibitors is a serious unmet need and numerous presentations were given at ASH 2020 in this space. A Phase I/II trial (NCT03740529) of LOXO-305, a novel reversible non-covalent BTK inhibitor, showed encouraging response rates in this high-risk population. Additionally, promising early data was seen from a Phase I trial (NCT03833180) of VLS-101: an investigational receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate that utilizes the monomethyl auristatin E cytotoxin. Dr Eyre also discusses a subgroup analysis of MCL patients in the TRANSCEND study (NCT02631044) of lisocabtagene maraleucel (liso-cel), a CAR-T cell therapy, which demonstrated high efficacy rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
